

## Commercial/Healthcare Exchange PA Criteria

*Effective: November 13, 2019*

**Prior Authorization:** Katerzia-Norliqva

**Products Affected:** Katerzia (amlodipine) oral suspension, Norliqva (amlodipine) oral solution

**Medication Description:** Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.

**Covered Uses:**

1. Hypertension
2. Coronary Artery Disease (CAD) including chronic stable angina, vasospastic angina (Prinzmetal's or variant angina), and angiographically documented CAD.

**Exclusion Criteria:**

1. Patients with known sensitivity to amlodipine

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried
3. Blood pressure

**Age Restrictions:** 6 years of age and older

**Prescriber Restrictions:** None

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Patient has a diagnosis of hypertension or Coronary Artery Disease (CAD) (chronic stable angina, vasospastic angina [Prinzmetal's or variant angina], and angiographically documented CAD); AND
- B. The patient is unable to ingest amlodipine oral tablets due to one of the following:
  - a. Oral/motor difficulties; OR
  - b. Dysphagia

**References:**

1. Katerzia [product insert]. Silvergate Pharmaceuticals Inc. Greenwood Village, CO. July 2019.
2. Katerzia. Lexicomp Online [Internet database], Hudson, Ohio: Wolters Kluwer Health, Inc; November 1, 2019.

3. Product Information: NORLIQVA(R) oral solution, amlodipine oral solution. CMP Pharma Inc (per FDA), Farmville, NC, 2022.

***Policy Revision history***

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	11/08/2019
2	Update Policy	Add Norliqva	Products Affected	6/23/2022